When was Taizong Biotechnology founded?

Taizong Biotechnology was founded in 1998.

Where is Taizong Biotechnology located?

Taizong Biotechnology is headquartered in Taipei, Taiwan.

How many employees does Taizong Biotechnology have?

As of Jun 30, 2026, the latest employee count at Taizong Biotechnology is 24.

Is Taizong Biotechnology a funded company?

Taizong Biotechnology is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Taizong Biotechnology rank among its competitors?

Taizong Biotechnology ranks 12th amongst 29 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Summit, which secured $228M in Oct, 2025.

Who are the top competitors of Taizong Biotechnology?

Taizong Biotechnology's top competitors include Inventiva Pharma, Genprex and DeuterOncology. Among them, Summit secured the most recent funding round in October, 2025.

Taizong Biotechnology - 2026 Company Profile & Competitors

Taizong Biotechnology is a public company based in Taipei (Taiwan), founded in 1998. It operates as a Developer of a platform for the detection and treatment of liver cancer. The company has 29 active competitors, including 8 funded and 6 that have exited. Its top competitors include companies like Inventiva Pharma, Genprex and DeuterOncology.

Company Details

Developer of a platform for the detection and treatment of liver cancer. The company has developed a tumour detection technology that uses hepatitis B virus chimaera DNA fragments (Catchimera) as tumour markers in liver cancer cells. It releases free DNA fragments in the liquid of tumour microenvironment that is used to screen and target the residual ctDNA (Circulating tumour DNA) in chronic type B Hepatitis patients. The company's proprietary drug molecules include PTX-9908 that is an injectable peptide drug used to block neovascularization in tumour cells in liver and U101 used to prevent urinary tract infection.

Key Metrics

Founded Year

1998

Location

Taipei, Taiwan

Stage

Public

Ranked

12^th among 29 active competitors

Employee Count

24 as on Jun 30, 2026

Similar Companies

Inventiva Pharma & 31 more

Exit Details

Public

View Taizong Biotechnology's full profile

Taizong Biotechnology got listed on May 07, 2012.

Click here to take a look at Taizong Biotechnology's IPO in detail

Taizong Biotechnology has not raised any funding rounds yet.

Taizong Biotechnology's employee count trend

Taizong Biotechnology has 24 employees as of Jun 26. Here is Taizong Biotechnology's employee count trend over the years:

Employee count trend for Taizong Biotechnology

Uncover Taizong Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Taizong Biotechnology include Inventiva Pharma, Genprex and DeuterOncology. Here is the list of Top 10 competitors of Taizong Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Inventiva Pharma 2012, Daix (France), Public	Provider of therapeutic solutions for fibrosis, lysosomal storage disorders and oncology	-	BVF Partners, Samsara BioCapital & 11 others	60/100
2nd	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
3rd	DeuterOncology 2020, Liege (Belgium), Acquired	Developer of therapeutics for lung cancer	$6.11M	Newton Biocapital, Capitaletcroissance.be ... & 2 others	50/100
4th	Bridge Biotherapeutics 2015, Seongnam-si (South Korea), Acquired	Developer of small molecule based therapeutics for the treatment of various diseases	$10M	SV Investment, HB Investment & 10 others	48/100
5th	GeneCraft 2020, Cheongju-si (South Korea), Series A	Developer of gene therapies for the treatment of cancer	$7.61M	Seoul National University, InfoBank	47/100
6th	Lamark Biotech 2018, Bengaluru (India), Seed	Developer of thermostable biologics for treating diabetes and other diseases	$983K	IKP Knowledge Park, Indian Angel Network & 7 others	45/100
7th	Flame Biosciences 2019, New York City (United States), Series B	Manufacturer of drugs for treating inflammation	$109M	TMCP, Hibiscus BioVentures	44/100
8th	Summit 2003, Menlo Park (United States), Public	Developer of therapeutics for oncology and rare diseases	-	Akeso	44/100
9th	Daan Biotherapeutics 2020, Seoul (South Korea), Series A	Developer of therapeutics for cancer treatment	$17.2M	Solasta Ventures, Solidus Investment & 9 others	38/100
10th	Dianhua 2009, China, Series C	Developer of therapeutics for the treatment of lung fibrosis	$15.7M	Shunwei Capital, 263 Network Communication Co ... & 4 others	35/100
12th	Taizong Biotechnology 1998, Taipei (Taiwan), Public	Developer of a platform for the detection and treatment of liver cancer	-	-	32/100